Houston, TX (PRWEB) June 21, 2011
Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing advanced biological processes that convert low-value feedstocks into high-value sustainable chemicals, today announced that the Company has hired Mr. Rashmi Shah as Vice President of GlycosBio’s subsidiary in Southeast Asia. This announcement marks another key milestone in GlycosBio’s expansion into Asia, as Mr. Shah will support the construction and commissioning of the Company’s industrial biochemical plant and biotechnology research and development facility in Bio-XCell, a dedicated biotechnology park in Johor, Malaysia. Construction of the plant will begin in Q3 2011 with an expected completion date in Q4 2012.
“Rashmi’s unique background and extensive experience in building and managing advanced petrochemical facilities in the United States and abroad will make him a tremendous asset to the GlycoBio’s management team. We are excited to have Rashmi join us in supporting the company’s expansion in Malaysia,” said Richard C. Cilento Jr., Chief Executive Officer of GlycosBio.
A seasoned oil and gas expert, including significant time leading expansion projects within Southeast Asia, Mr. Shah brings extensive experience handling startup planning and execution, multinational staff development, management and process design and development. In addition, Rashmi is recognized as an expert in developing and implementing organization effectiveness, processes, benchmarking and best practices.
“I am pleased to join GlycosBio. Leading the commissioning of an advanced biochemical facility allows me to utilize my diverse International expertise and build upon my petrochemical and engineering background. I look forward to supporting GlycosBio’s commercialization efforts in producing isoprene to support Malaysia’s rubber industry and meeting the growing global demand for clean, environmentally safe biochemicals,” said Mr. Shah.
About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.
GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals. For more information, visit http://www.glycosbio.com.
# # #